Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Inclusion Criteria : * Aged 2 to 45 years on the day of inclusion. * Provision of Informed Consent/Assent Form signed by the participant (and/or by the parent or another legally acceptable representative for participants \<18 years). * Participant (and parent/guardian for participants \<18 years) able to attend all scheduled visits and to comply with all trial procedures. * For a female participant of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination. * Participant in good health, based on medical history, physical examination and laboratory parameters. Exclusion Criteria : * Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia. * For a female participant of child-bearing potential, known pregnancy or positive serum pregnancy test at Screening. * For a female participant of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of the first injection. * Breast-feeding female participant. * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination. * Human immunodeficiency virus, hepatitis B, or hepatitis C seropositivity in the blood sample taken at screening. * Planned participation in another clinical trial during the first year of the study. * Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such …